Results
non-alcoholic fatty liver disease
NON-ALCOHOLIC FATTY LIVER DISEASE
The study was conducted between December 2021 and the spring, summer, and fall of 2022, and it involved adult patients diagnosed with non-alcoholic fatty liver disease who met the predetermined inclusion criteria. Prior to their participation, written informed consent was obtained from all individuals. A total of 78 participants were enrolled and randomly allocated to either the pomegranate peel group or the placebo group, utilizing a stratified block design to ensure equal distribution. Specifically, 39 participants were assigned to the pomegranate peel group, while the remaining 39 were assigned to the placebo group. The participants were then observed and followed up for a duration of 8 weeks. During the study period, the majority of patients adhered to their assigned treatment, with only two individuals from the placebo group discontinuing their participation. The flow diagram of participant selection process and study procedure is illustrated in Fig. Gastrointestinal symptom severity rating (GSSR) did not change significantly within (P = 0.29 and 0.54, respectively) and also between (P = 0.64) pomegranate peel and placebo group when measured in different time sequences. The quality assessment of the extract reported the mean polyphenol content (ellagic acid)/gram of 15%.
The flow diagram of participant selection process and study procedure